Form 4: Alkermes EVP Craig Hopkinson Executes Stock Option Sale

Alkermes EVP and Chief Medical Officer Craig C. Hopkinson exercised options and sold 9,000 shares under a 10b5-1 plan.

Summary

• Craig C. Hopkinson, EVP R&D and Chief Medical Officer, exercised 5,000 stock options at a price of $19.34 per share.
• Following the exercise, a total of 9,000 ordinary shares were sold at a weighted average price of $33.3955 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on March 14, 2025.
• The reporting person's beneficial ownership of ordinary shares now stands at 81,389.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the transaction was pre-planned and represents standard executive financial management.

Positives

• The transaction was pre-planned under a Rule 10b5-1 trading plan, indicating the sale was not based on sudden non-public information.

Negatives

• The executive reduced his direct equity stake in the company by 4,000 net shares.

Risks

• None identified in this specific Form 4 filing.

Future Outlook

No forward-looking guidance provided in this document.

Industry Context

StockSavvy.ai notes that routine insider selling via 10b5-1 plans is standard corporate practice for executives managing personal liquidity and is generally not indicative of a change in company outlook.

Comparison to Industry Standards

• The use of Rule 10b5-1 plans is the industry standard for executives to avoid potential conflicts of interest regarding insider trading regulations.

Stakeholder Impact

• Minimal impact on shareholders as the sale was conducted through a pre-arranged 10b5-1 plan.

Key Dates

Keywords

Alkermes, ALKS, Insider Trading, Form 4, Craig Hopkinson, Stock Options